a close up of a pen


Frontage Laboratories completes acquisition of Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.

On August 16, 2023, Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc. (Frontage), completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc.

Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services.  In addition, it provides consulting services, especially in quality control and assurance as well as in Natural Health Product Regulations.

Nucro-Technics, located in the Toronto, Canada metropolitan area, operates in a state-of-the-art 60,000 square foot facility and employs personnel having expertise in testing both large and small molecules designed to treat various medical conditions.

Frontage is a global and full service Contract Research Organization (CRO) which provides integrated product development services from drug discovery to late phase clinical process.

BLG represented Frontage with a team led by Vinay Desai that included Carlos Cerqueira, Stephen Roumeliotis and Kate Cassidy (Corporate); Denes Rothschild (Competition); Joe Takhmizdjian (Tax); Andrew Guerrisi (Real Estate); Denisa Mertiri (Environmental); Odessa O'Dell and Neva Lyn Kew (Labour & Employment).